Journal article
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. The researchers studied infants 6 to 12 weeks of age recruited for the same trial.The study concludes that the RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants.
Languages
- English
Publication year
2012
Journal
The New England Journal of Medicine
Volume
367
Issue
24
Type
Journal article
Categories
- Vaccines & delivery devices
Diseases
- Malaria
Countries
- Africa
Tags
- New vaccine introduction
